Inotrem will attend Immunotherapies & Innovations For Infectious Diseases 6th Congress. It is looking forward to meeting you at its lecture presenting the results of its last two clinical trials, ASTONISH and ESSENTIAL, targeting TREM-1 for the treatment of Septic Shock and Critically-Ill COVID-19 patients.
Paris (France), October 25. 2022. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, announced today at the European Society of Intensive Care Medicine’s Annual Congress, held in Paris, positive results for ESSENTIAL, its Phase II clinical trial in COVID-19 patients hospitalized in
Inotrem is pleased to attend the European Society of Intensive Care Medicine’s 35th Annual Congress in Paris where it will be holding a Symposium on “Targeting TREM-1 to Manage Life-Threatening Immune Disorders Caused by Severe Infections”
Inotrem welcomes you at the Symposium it will be holding during ISICIP 2022 on “Correcting Severe Immune Dysregulations in Sever Infections. The role of the TREM-1 Pathway. Applications in Septic Shock and COVID-10”.
Paris (France), October 13, 2022. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, disclosed for the first time today at the International Sepsis Forum held in Barcelona the results for its Phase IIb ASTONISH clinical trial in septic shock patients.
Paris (France), May 31. 2022. Inotrem, an advanced clinical stage biotech company developing TREM- 1 targeting immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Luke Beshar as Chairman of its Board of Directors, effective May 25, 2022. Mr. Beshar succeeds Thierry Hercend who served as Chairman
BioEquity Europe, Milan, May 16-18, 2022. Inotrem is pleased to attend BioEquity Europe that will take place in Milan on May 16-18, 2022
LIVES 40, Madrid, May 12-14, 2022. The European Society of Intensive Care Medicine (ESICM) celebrates its 40th anniversary with a three-days event in Madrid.
Paris (France), April 14th 2022. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD.
Paris, March 17, 2022. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Laurent Vincens as Chief Technology Officer and Head of Manufacturing. The newly created position comes as the company is rapidly advancing its TREM-1 pathway focused
March 1-2. 2022, Sachs European Life-Science CEO Forum (on line). Inotrem will participate to the 15th Annual European Life Sciences CEO Forum (ELSF) that will take place on the 1st-2nd of March 2022 and is part of the Sachs Spring Life Sciences Week. Inotrem is pleased to participate to this global bio-pharma industry event and, through
Geneva, Switzerland, and Paris, France, January 19, 2022 – Selexis SA, a JSR Life Sciences company, and Inotrem SA, an advanced clinical-stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, have signed a service agreement to develop the cell line for Inotrem’s antibody-based candidate to address chronic
Paris, France. November 9, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies targeting the TREM-1 pathway, announced today the appointment of Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program. The creation of this position comes at a time of significant growth for Inotrem as
November 15-16. 2021. Lyon, France. Inotrem is pleased to participate to the fifth edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2021). Fostering quality interactions between hundreds of pharmaceutical companies, research labs, service providers, technology developers, and clinicians, I4ID has become a central event contributing to the development of
Paris, July 12th. 2021. Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities.
Paris. June 23, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that it has filed a patent to protect a new therapeutic modality against TREM-1, a monoclonal antibody.
Paris. June 10th, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that the ASTONISH Independent Data Monitoring Committee (IDMC) completed the planned safety and efficacy assessment for futility of the company’s ongoing Phase IIB ASTONISH trial in septic shock
Paris. March 24, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Sven Zimmermann as Chief Executive Officer, effective April 19th, 2021. Sven brings an extensive leadership experience in biotech companies’ financial and corporate strategy.
March 16-17. 2021 (fully digital format). Inotrem is thrilled to participate to HYBRID 2021, the first Health Bioscience Research Industry Days that represents the complete ecosystem in life science in France, organized by ARIIS, AVIESAN, Leem, BPI France and France Biotech. During two days, researchers, biotech companies and representatives of
Paris, Limoges, Nancy (France). February 3rd, 2021 – Today, the CoviTREM-1 consortium, regrouping Nancy and Limoges teaching hospitals with Inotrem, a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, announces that it has completed the patients’ inclusion of its Phase IIa clinical study with a total of 60 patients
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2022 – Legal notices
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2022- Legal notices